+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acid sphingomyelinase deficiency (ASMD) - Epidemiology Forecast to 2032

  • ID: 4845143
  • Report
  • January 2022
  • Region: Global
  • 60 Pages
  • DelveInsight
This "Acid sphingomyelinase deficiency (ASMD) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Acid sphingomyelinase deficiency (ASMD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Acid sphingomyelinase deficiency (ASMD) Understanding


The Acid sphingomyelinase deficiency (ASMD) epidemiology report gives a thorough understanding of the Acid sphingomyelinase deficiency (ASMD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Acid sphingomyelinase deficiency (ASMD) in the US, Europe, and Japan. The report covers the detailed information of the Acid sphingomyelinase deficiency (ASMD) epidemiology scenario in seven major countries (US, EU5, and Japan).

Acid sphingomyelinase deficiency (ASMD) Epidemiology Perspective


The Acid sphingomyelinase deficiency (ASMD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Acid sphingomyelinase deficiency (ASMD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Acid sphingomyelinase deficiency (ASMD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Acid sphingomyelinase deficiency (ASMD) Detailed Epidemiology Segmentation


The Acid sphingomyelinase deficiency (ASMD) epidemiology covered in the report provides historical as well as forecasted Acid sphingomyelinase deficiency (ASMD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The Acid sphingomyelinase deficiency (ASMD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The Acid sphingomyelinase deficiency (ASMD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Acid sphingomyelinase deficiency (ASMD) Epidemiology Report and Model provide an overview of the global trends of Acid sphingomyelinase deficiency (ASMD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Acid sphingomyelinase deficiency (ASMD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Acid sphingomyelinase deficiency (ASMD)
  • The report provides the segmentation of the Acid sphingomyelinase deficiency (ASMD) epidemiology

Report Highlights

  • 11-year Forecast of Acid sphingomyelinase deficiency (ASMD) epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Acid sphingomyelinase deficiency (ASMD)
  • Cases of Acid sphingomyelinase deficiency (ASMD) by Mutation Types
  • Acid sphingomyelinase deficiency (ASMD) Cases associated with Clinical Manifestations

KOL views


The publisher interviews, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acid sphingomyelinase deficiency (ASMD)?
  • What are the key findings pertaining to the Acid sphingomyelinase deficiency (ASMD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of patients of Acid sphingomyelinase deficiency (ASMD) across the 7MM during the forecast period (2019-2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
  • What is the disease risk, burden and unmet needs of Acid sphingomyelinase deficiency (ASMD)?
  • What are the currently available treatments of Acid sphingomyelinase deficiency (ASMD)?

Reasons to Buy


The Acid sphingomyelinase deficiency (ASMD) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Acid sphingomyelinase deficiency (ASMD) market
  • Quantify patient populations in the global Acid sphingomyelinase deficiency (ASMD) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Acid sphingomyelinase deficiency (ASMD) therapeutics in each of the markets covered
  • Understand the magnitude of Acid sphingomyelinase deficiency (ASMD) population by its epidemiology
  • The Acid sphingomyelinase deficiency (ASMD) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown

1. Key Insights2. Executive Summary of Acid sphingomyelinase deficiency (ASMD)
3. Acid sphingomyelinase deficiency (ASMD): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
5.4.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in Germany (2019- 2032)
5.5.2. France Epidemiology
5.5.2.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in France (2019- 2032)
5.5.3. Italy Epidemiology
5.5.3.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in Italy (2019- 2032)
5.5.4. Spain Epidemiology
5.5.4.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in Spain (2019- 2032)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
5.6.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in Japan (2019- 2032)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Acid sphingomyelinase deficiency (ASMD) Treatment and Management
6.2. Acid sphingomyelinase deficiency (ASMD) Treatment Algorithm
7. KOL Views8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. Publisher Capabilities11. Disclaimer
12. About the Publisher
*The table of contents is not exhaustive; will be provided in the final report
List of Tables
Table 1: Acid sphingomyelinase deficiency (ASMD) Epidemiology in 7MM (2019-2032)
Table 2: Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Acid sphingomyelinase deficiency (ASMD) Epidemiology in the United States (2019-2032)
Table 4: Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Acid sphingomyelinase deficiency (ASMD) Epidemiology in Germany (2019-2032)
Table 6: Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Acid sphingomyelinase deficiency (ASMD) Epidemiology in France (2019-2032)
Table 8: Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Acid sphingomyelinase deficiency (ASMD) Epidemiology in Italy (2019-2032)
Table 10: Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Acid sphingomyelinase deficiency (ASMD) Epidemiology in Spain (2019-2032)
Table 12: Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Acid sphingomyelinase deficiency (ASMD) Epidemiology in the United Kingdom (2019-2032)
Table 14: Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Acid sphingomyelinase deficiency (ASMD) Epidemiology in Japan (2019-2032)
Table 16: Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Japan (2019-2032)
List of Figures
Figure 1 Acid sphingomyelinase deficiency (ASMD) Epidemiology in 7MM (2019-2032)
Figure 2 Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Acid sphingomyelinase deficiency (ASMD) Epidemiology in the United States (2019-2032)
Figure 4 Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Acid sphingomyelinase deficiency (ASMD) Epidemiology in Germany (2019-2032)
Figure 6 Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Acid sphingomyelinase deficiency (ASMD) Epidemiology in France (2019-2032)
Figure 8 Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Acid sphingomyelinase deficiency (ASMD) Epidemiology in Italy (2019-2032)
Figure 10 Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Acid sphingomyelinase deficiency (ASMD) Epidemiology in Spain (2019-2032)
Figure 12 Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Acid sphingomyelinase deficiency (ASMD) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Acid sphingomyelinase deficiency (ASMD) Epidemiology in Japan (2019-2032)
Figure 16 Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report
Note: Product cover images may vary from those shown